A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Conditions

• Colorectal Cancer

Interventions

• DRUG: Oxaliplatin 130 mg/m^2
• DRUG: Capecitabine 1000 mg/m^2
• DRUG: Bevacizumab 7.5 mg/kg
• DRUG: Placebo for bevacizumab 7.5 mg/kg
• DRUG: Oxaliplatin 85 mg/m^2
• DRUG: Leucovorin 200 mg/m^2
• DRUG: Fluorouracil 400 mg/m^2
• DRUG: Bevacizumab 5 mg/kg
• DRUG: Placebo for bevacizumab 5 mg/kg

Sponsor

Hoffmann-La Roche